Laboratoires Théa

Laboratoires Théa is a privately held, fully integrated ophthalmology company with a global commercial footprint and a vertically integrated '100% made in Europe' manufacturing model. Its core business is built on a portfolio of commercial products addressing common eye conditions like dry eye, glaucoma, allergies, and infections, while actively investing in a diversified R&D pipeline through internal development and strategic partnerships. The company is led by its founding family, emphasizes corporate social responsibility with a stated carbon neutrality goal by 2045, and is expanding its pipeline into novel therapeutic areas such as myopia progression and genetic retinal diseases.

Specialized in preservative-free (PF) ophthalmic formulations and advanced aseptic manufacturing. Expanding technology base through Open Innovation to include RNA therapy and other novel modalities for anterior and posterior segment diseases.

Théa competes in a crowded global ophthalmology market against large-cap pharma (e.g., Novartis, Roche, AbbVie) and established pure-play ophthalmic companies (e.g., Santen, Bausch + Lomb). Its differentiation is built on preservative-free expertise, a fully integrated European manufacturing model, and a focused R&D strategy targeting specific unmet needs like myopia progression and orphan retinal diseases.